BAYZED HEALTH's stock price surged 5.17% during intraday trading on Wednesday, following the release of its annual results for the fiscal year 2025.

The company reported a 5.8% year-on-year decline in revenue to RMB 1.12 billion. However, key profitability metrics showed significant improvement, with adjusted net profit climbing 43.2% to RMB 17.94 million and adjusted EBITDA growing 10.6% to RMB 144.36 million. The adjusted EBITDA margin also expanded to 12.9% from 11.4% a year earlier.

Investors appeared to focus on the company's strengthened financial position, highlighted by a 31.9% jump in net operating cash inflow to a record high of RMB 222.34 million. Cash and cash equivalents more than doubled to RMB 616.0 million, supported by IPO proceeds, while the gearing ratio improved substantially to 36.6% from 46.9%.